ROIV ROIVANT SCIENCES LTD Investments/Divestments 8-K Filing 2024 - Other Events Roivant Sciences announced positive study results for brepocitinib and a $1.5 billion share repurchase program, including repurchase of shares held by Sumitomo Pharma.Get access to all SEC 8-K filings of the ROIVANT SCIENCES LTD